Results of part B of a phase 1b trial showed that the addition of isatuximab (using the short-duration, fixed-volume infusion method) to standard-of-care VRd was feasible, safe, and effective in patients with NDMM ineligible or with no immediate intent for ASCT. Read More ›

Updated results of the KarMMa trial showed that ide-cel CAR T-cell therapy resulted in durable and deep responses in heavily pretreated, triple-class–exposed patients with RRMM, supporting an overall favorable clinical benefit–risk profile. Read More ›

Data from the ongoing phase 1/2 MajesTEC-1 study suggested that treatment with the BCMA x CD3 bispecific antibody teclistamab induced deep and durable responses in heavily pretreated patients with RRMM, with a manageable safety profile. Read More ›

The 18-month longer follow-up results of the ANDROMEDA study demonstrated sustained clinical benefits of D-VCd versus VCd in terms of hematologic and organ responses in patients with newly diagnosed light chain amyloidosis, with no additional safety signals. Read More ›

Corneal event management guidelines were developed with the goal of assisting practicing hematologists/oncologists in assessing and managing belantamab mafodotin–associated ocular events so that patients may continue to maximize clinical benefit with belantamab mafodotin therapy. Read More ›

Results of the phase 2 HOVON 143 study indicate that ixazomib, daratumumab, and dexamethasone is an effective and feasible regimen in intermediate-fit patients with non–transplant-eligible NDMM. Read More ›

Results of a phase 2 IFM study demonstrated that quadruplet combination regimen of D-IRD as induction and consolidation therapy after ASCT followed by lenalidomide maintenance therapy was safe and resulted in increased depth of responses over time in standard-risk patients with NDMM. Read More ›

A simulation modeling that incorporated clinically representative sequences for patients with transplant-ineligible NDMM and included attrition rates supports using the D-Rd regimen in the first-line setting instead of reserving it for later lines of therapy. Read More ›

Findings of the multicohort phase 1 TRIMM-2 trial showed that the G-protein–coupled receptor family C group 5 member D x CD3 bispecific antibody talqueta­mab in combination with daratumumab therapy was well-tolerated and resulted in promising antitumor activity in patients with RRMM, supporting further evaluation of this combination. Read More ›

A subgroup analysis of the FORTE study found that carfilzomib-lenalidomide-dexamethasone induction/consolidation (KRd) plus ASCT and carfilzomib-lenalidomide maintenance provided survival benefit to patients of all cytogenetic risk groups, including patients at high risk. Read More ›

Page 1 of 3

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: